Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results
Horizon: A Differentiated Investment Opportunity
We are a leading, high-growth profitable biopharma company
⚫ Differentiated commercial model; generating annual net sales of $1.3B only 8 years post IPO
•
•
Focused on rare diseases and presence in rheumatology, nephrology, ophthalmology and endocrinology
Two high-growth drivers with >$2B in combined peak U.S. annual net sales potential(1)
呂
Delivering innovative therapies to patients
Deep development expertise with proven track record
.
Building a pipeline through M&A to support sustainable long-term growth
123.7%
85.3%
$
Generating high returns for shareholders
38.7%
25.1%
• Outperformed NBI for 1, 3, 5 years
Our prospects position us with a top-tier growth profile
1-year
3-year
HZNP
(1) Horizon estimate.
HI HORIZON
180.8%
21.9%
5-year
NBI (Nasdaq Biotechnology Index)
Total Shareholder Return through Dec. 31, 2019
4View entire presentation